Last $83.31 USD
Change Today -0.07 / -0.08%
Volume 49.8K
ICUI On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

icu medical inc (ICUI) Key Developments

ICU Medical, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 01:00 PM

ICU Medical, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 01:00 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States.

ICU Medical, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Year 2014

ICU Medical, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's net sales were $77,329,000 against $82,709,000 a year ago. Total revenue was $77,457,000 against $82,815,000 a year ago. Income from operations was $8,409,000 against $15,416,000 a year ago. Income before income taxes was $8,564,000 against $15,606,000 a year ago. Net income was $6,428,000 or $0.42 diluted per share against $11,034,000 or $0.72 diluted per share a year ago. Adjusted EBITDA was $18,911,000 against $22,560,000 a year ago. Adjusted diluted earnings per share were $0.66 against $0.84 a year ago. This decline in adjusted EBITDA was primarily due to lower sales and increased R&D expenditures. The decrease in adjusted diluted earnings per share was primarily due to lower revenue, higher noncash-based stock compensation expense and the increased R&D, was slightly offset by lower tax rate. For the nine months, the company's net sales were $228,997,000 against $235,419,000 a year ago. Total revenue was $229,364,000 against $235,775,000 a year ago. Income from operations was $26,984,000 against $38,391,000 a year ago. Income before income taxes was $27,556,000 against $38,961,000 a year ago. Net income was $18,963,000 or $1.22 diluted per share against $27,086,000 or $1.79 diluted per share a year ago. Net cash provided by operating activities was $48,347,000 against $42,244,000 a year ago. Purchases of property and equipment was $14,924,000 against $15,223,000 a year ago. Intangible asset additions was $709,000 against $839,000 a year ago. Adjusted EBITDA was $52,028,000 against $58,886,000 a year ago. Adjusted diluted earnings per share were $1.71 against $2.11 a year ago. For the year 2014, the company now expects revenue to be in the range of $304 million to $307 million, compared to the previous range of $285 million to $300 million. GAAP diluted earnings per share increased to a range of $1.62 to $1.70 compared to the previous range of $1.30 to $1.45. Adjusted diluted earnings per share increased to a range of $2.25 to $2.33 compared to the previous range of $1.95 to $2.15, and adjusted EBITDA is increased to a range of $69 million to $71 million compared to the previous range of $63 million to $68 million. GAAP net income to be $25,094,000 to $26,363,000 a year ago. Depreciation and amortization expense to be $19,640,000.

ICU Medical, Inc. to Report Q3, 2014 Results on Nov 10, 2014

ICU Medical, Inc. announced that they will report Q3, 2014 results at 4:00 PM, US Eastern Standard Time on Nov 10, 2014

ICU Medical, Inc., Q3 2014 Earnings Call, Nov 10, 2014

ICU Medical, Inc., Q3 2014 Earnings Call, Nov 10, 2014

ICU Medical Announces Study Results of ChemoClave Closed System Transfer Device and MicroClave Neutral Displacement Connector

ICU Medical, Inc. announced that a new study presented this week at the 38(th) Annual Association of Pediatric Hematology/Oncology Nurses (APHON) Conference in Portland, OR showed that the company's ChemoClave(R) closed system transfer device (CSTD) contributed to a significant reduction in chemotherapy spills and exposures, while a switch to ICU Medical's MicroClave(R) Clear neutral displacement connector from the MaxPlus(R) positive pressure connector (CareFusion Corporation, San Diego, CA) contributed to a reduction in central line-associated bloodstream infections (CLABSI). To test the ChemoClave system's ability to limit chemotherapy spills and exposures, clinicians in the pediatric oncology unit recorded the number of times they entered a patient's line over a 24-hour period and documented any leaks at the connection site both before and after ChemoClave implementation. Before implementation of the ChemoClave system, clinicians recorded a total of 23 potential exposures out of the 24 times a patient's line was entered. Following implementation, use of the ChemoClave system was associated with 0 potential exposures out of the 47 times a patient's line was entered in a 24-hour period.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICUI:US $83.31 USD -0.07

ICUI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cyberonics Inc $55.06 USD +0.43
Merit Medical Systems Inc $17.35 USD +0.18
Thoratec Corp $32.91 USD +0.10
Tornier NV $25.46 USD -0.22
Wright Medical Group Inc $26.57 USD -0.08
View Industry Companies
 

Industry Analysis

ICUI

Industry Average

Valuation ICUI Industry Range
Price/Earnings 40.1x
Price/Sales 4.2x
Price/Book 2.6x
Price/Cash Flow 39.6x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ICU MEDICAL INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.